IL140483A0 - Compounds obtained from saliva species having antiviral activity - Google Patents

Compounds obtained from saliva species having antiviral activity

Info

Publication number
IL140483A0
IL140483A0 IL14048399A IL14048399A IL140483A0 IL 140483 A0 IL140483 A0 IL 140483A0 IL 14048399 A IL14048399 A IL 14048399A IL 14048399 A IL14048399 A IL 14048399A IL 140483 A0 IL140483 A0 IL 140483A0
Authority
IL
Israel
Prior art keywords
saliva
species
antiviral activity
compounds obtained
compounds
Prior art date
Application number
IL14048399A
Other languages
English (en)
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of IL140483A0 publication Critical patent/IL140483A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F246/00Copolymers in which the nature of only the monomers in minority is defined
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL14048399A 1998-06-25 1999-06-25 Compounds obtained from saliva species having antiviral activity IL140483A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/104,363 US6037369A (en) 1998-06-25 1998-06-25 Compounds obtained from salvia species having antiviral Activity
PCT/US1999/014297 WO1999066942A1 (en) 1998-06-25 1999-06-25 Compounds obtained from salvia species having antiviral activity

Publications (1)

Publication Number Publication Date
IL140483A0 true IL140483A0 (en) 2002-02-10

Family

ID=22300096

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14048399A IL140483A0 (en) 1998-06-25 1999-06-25 Compounds obtained from saliva species having antiviral activity

Country Status (18)

Country Link
US (1) US6037369A (xx)
EP (1) EP1089747A1 (xx)
JP (1) JP2002518455A (xx)
KR (1) KR20010071580A (xx)
CN (1) CN1312722A (xx)
AU (1) AU740698B2 (xx)
BR (1) BR9912218A (xx)
CA (1) CA2335956A1 (xx)
CZ (1) CZ20004858A3 (xx)
HU (1) HUP0103398A2 (xx)
ID (1) ID28792A (xx)
IL (1) IL140483A0 (xx)
IS (1) IS5792A (xx)
MX (1) MXPA01000195A (xx)
NO (1) NO20006631L (xx)
PL (1) PL345086A1 (xx)
TR (1) TR200100450T2 (xx)
WO (1) WO1999066942A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024460A1 (en) * 1996-12-05 1998-06-11 Georgetown University Extracts of salvia species having antiviral activity
US6043276A (en) * 1998-06-25 2000-03-28 Georgetown University School Of Medicine Compounds obtained from salvia species having antiviral activity
WO2001085189A1 (de) * 2000-05-05 2001-11-15 Parsenn-Produkte Ag Zubereitung zur topischen behandlung von durch virusinfektionen verursachten manifestationen
SG98409A1 (en) * 2000-06-21 2003-09-19 Chi Chiang Yang Pharmaceutical compositions and combinations for the treatment or prophylaxis of disorders related to hiv and retrovirus
JP2002020283A (ja) * 2000-06-22 2002-01-23 Yang Chi-Chiang Hivおよびレトロウイルスに関連する障害の処置または予防のための薬学的組成物および組み合わせ
KR20020005222A (ko) * 2000-06-28 2002-01-17 치-치앙 양 Hiv 또는 레트로바이러스에 관련된 질환의 치료 또는예방용 약학적 조성물 및 조합물
US7071227B2 (en) * 2000-09-26 2006-07-04 The Johns Hopkins University Antiviral compositions and methods of use
US20070027209A1 (en) * 2005-08-01 2007-02-01 Lee Hyun C Prevention and treatment of atherosclerosis with lithospermate B
WO2008117901A1 (en) * 2007-03-28 2008-10-02 Industry-Academic Cooperation Foundation, Yonsei University A method for isolation of high concentration of magnesium lithospermate b from salviae miltiorrhizae
AU2010230770B2 (en) * 2009-03-30 2014-07-03 Tasly Pharmaceutical Group Co., Ltd. New salvianolic acid compound L, preparation method and use thereof
CN101919836A (zh) * 2009-06-17 2010-12-22 山东绿叶天然药物研究开发有限公司 迷迭香酸的新用途
CN103054976B (zh) * 2011-10-21 2014-09-24 上海中医药大学 一种治疗血小板减少症的中药组合物及其制备方法和应用
CN103845403B (zh) * 2014-02-27 2016-10-05 河南大学 丹参配方颗粒在制备预防和治疗艾滋病脑病药物方面的应用
CN104974119B (zh) * 2014-04-01 2018-10-19 中国科学院上海药物研究所 一种高纯度丹酚酸b镁及其制备方法
CN108042524A (zh) * 2017-12-21 2018-05-18 南方医科大学 丹酚酸b及其结构类似物在制备抗hpv病毒感染药物中的应用
CN109771410B (zh) * 2019-03-06 2020-11-24 湖北大学 紫草酸在制备抗乙肝病毒药物中的用途
CN109771407B (zh) * 2019-03-29 2021-11-26 成都医学院 迷迭香酸在制备抑制水痘-带状疱疹病毒的药物中的用途
CN110922286B (zh) * 2019-11-23 2022-08-16 上海化工研究院有限公司 一种非对称芳基取代富烯化合物及其制备方法与应用
US20230210848A1 (en) * 2020-04-30 2023-07-06 Fujifilm Toyama Chemical Co., Ltd. Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
CN114712342B (zh) * 2022-05-10 2023-04-21 湖北大学 紫草酸在制备抗流感病毒药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178865A (en) * 1990-06-19 1993-01-12 Cedars-Sinai Medical Center Chinese herbal extracts in the treatment of hiv related disease in vitro
US5346695A (en) * 1991-03-27 1994-09-13 Tampa Bay Research Institute Methods of inhibiting HIV replication in vitro using polymers of p-hydroxylated cinnamic acids
WO1998024460A1 (en) * 1996-12-05 1998-06-11 Georgetown University Extracts of salvia species having antiviral activity

Also Published As

Publication number Publication date
WO1999066942A1 (en) 1999-12-29
AU740698B2 (en) 2001-11-15
ID28792A (id) 2001-07-05
KR20010071580A (ko) 2001-07-28
HUP0103398A2 (hu) 2002-01-28
NO20006631L (no) 2001-02-26
EP1089747A1 (en) 2001-04-11
JP2002518455A (ja) 2002-06-25
CZ20004858A3 (cs) 2001-09-12
PL345086A1 (en) 2001-12-03
TR200100450T2 (tr) 2001-07-23
BR9912218A (pt) 2002-07-23
MXPA01000195A (es) 2002-04-24
NO20006631D0 (no) 2000-12-22
CN1312722A (zh) 2001-09-12
WO1999066942A9 (en) 2000-06-22
CA2335956A1 (en) 1999-12-29
IS5792A (is) 2000-12-22
US6037369A (en) 2000-03-14
AU4714999A (en) 2000-01-10

Similar Documents

Publication Publication Date Title
IL140483A0 (en) Compounds obtained from saliva species having antiviral activity
GB9815567D0 (en) Antiviral compound
PL348041A1 (en) Thrombopoietic compounds
GB9807354D0 (en) Antiviral compound
EP1131314A4 (en) CONNECTIONS WITH CYTOKIN INHIBITOR ACTIVITY
EP1206255A4 (en) CONNECTIONS FROM SALVIA SPECIES WITH ANTIVIRAL EFFECTIVENESS
GB9807355D0 (en) Antiviral compound
SI1069894T1 (sl) Sestavine spisulosina, ki imajo protitumorsko aktivnost
GB9803246D0 (en) Novel Compounds
GB9802826D0 (en) Novel compounds
GB9802533D0 (en) Novel compounds
GB9802387D0 (en) Novel compounds
GB9801882D0 (en) Novel compounds
GB9801635D0 (en) Novel compounds
GB9801634D0 (en) Novel compounds
GB9801633D0 (en) Novel compounds
GB9801632D0 (en) Novel compounds
GB9801630D0 (en) Novel compounds
GB9800337D0 (en) Novel compounds
GB9800324D0 (en) Novel compounds
GB9803306D0 (en) Novel compounds
GB9803290D0 (en) Novel compounds
GB9803289D0 (en) Novel compounds
GB9802804D0 (en) Novel compounds
GB9803194D0 (en) Novel compounds